364 related articles for article (PubMed ID: 15037231)
1. Strategies for dealing with metabolite elucidation in drug discovery and development.
Nassar AE; Talaat RE
Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
[TBL] [Abstract][Full Text] [Related]
2. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
3. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
4. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
5. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
6. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
7. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
Nassar AE; Kamel AM; Clarimont C
Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
[TBL] [Abstract][Full Text] [Related]
8. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
Castro-Perez JM
Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
[TBL] [Abstract][Full Text] [Related]
9. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
[No Abstract] [Full Text] [Related]
10. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
11. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
12. Metabolites in safety testing: metabolite identification strategies in discovery and development.
Nedderman AN
Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
[TBL] [Abstract][Full Text] [Related]
13. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
[TBL] [Abstract][Full Text] [Related]
14. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
15. Lead optimization strategies as part of a drug metabolism environment.
Korfmacher WA
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
[TBL] [Abstract][Full Text] [Related]
16. [Research in the field of clinical pharmacology in the USSR].
Lakin KM; Makarov VA; Novikova NV
Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
[TBL] [Abstract][Full Text] [Related]
17. Modelling of the blood-brain barrier in drug discovery and development.
Cecchelli R; Berezowski V; Lundquist S; Culot M; Renftel M; Dehouck MP; Fenart L
Nat Rev Drug Discov; 2007 Aug; 6(8):650-61. PubMed ID: 17667956
[TBL] [Abstract][Full Text] [Related]
18. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
Humphreys WG; Unger SE
Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
[TBL] [Abstract][Full Text] [Related]
20. In vivo metabolite detection and identification in drug discovery via LC-MS/MS with data-dependent scanning and postacquisition data mining.
Triolo A; Altamura M; Dimoulas T; Guidi A; Lecci A; Tramontana M
J Mass Spectrom; 2005 Dec; 40(12):1572-82. PubMed ID: 16320289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]